RARE DISEASERESEARCH ATLAS

ORPHA:79325

ALG8-CDG

medium confidenceDisorder

Also known as: CDG syndrome type Ih · CDG-Ih · CDG1H · Carbohydrate deficient glycoprotein syndrome type Ih · Congenital disorder of glycosylation type 1h · Congenital disorder of glycosylation type Ih · Glucosyltransferase 2 deficiency

Query health: suspect — Only one of 3 strategies returned hits (phrase).

Publications

100

58.4th percentile

Trials

0

Interventional, condition-specific

Researchers

743

Distinct authors in sample

Gene link

ALG8

Definitive

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare form of disorders of N-linked glycosylation characterized by gastrointestinal symptoms (diarrhea, vomiting, feeding problems with , protein-losing enteropathy), edema and ascites (including hydrops fetalis), , renal tubulopathy, coagulation anomalies due to thrombocytopenia, brain involvement (psychomotor delay, , ), facial dysmorphism (low-set ears and retrognathia), pes equinovarus, and muscular . Cataracts may also be observed. Prognosis is usually poor. The disease is caused by loss-of-function mutations in the gene ALG8 (11q14.1), resulting in a block in the initial step of protein glycosylation.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (5)

ALG8-congenital disorder of glycosylation · carbohydrate deficient glycoprotein syndrome type Ih · congenital disorder of glycosylation type 1h · congenital disorder of glycosylation type Ih · glucosyltransferase 2 deficiency

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — ALG8

  2. LiteraturePresent

    100 matched papers (65 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (ALG8).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

100

100 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

100 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

65 in the last 10 years · medium confidence · 58.4th percentile (publications denominator)

Phrase hits: 100 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

743

Distinct author names in 100 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Freeze HH13 papers · 2024

    Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.

    Papers in Europe PMC
  2. 02
    Jaeken J13 papers · 2023

    Center for Metabolic Diseases, University Hospital of Leuven, Leuven, Belgium.

    Papers in Europe PMC
  3. 03
    Morava E13 papers · 2025

    Radboud University Nijmegen Medical Centre, Institute for Genetic and Metabolic Disease, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. E.Morava@cukz.umcn.nl

    Papers in Europe PMC
  4. 04
    Ng BG9 papers · 2024

    Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.

    Papers in Europe PMC
  5. 05
    Barone R6 papers · 2024

    Pediatric Neurology Policlinico, University of Catania, Catania, Italy.

    Papers in Europe PMC
  6. 06
    Lefeber DJ6 papers · 2022

    Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, 6525 Nijmegen, the Netherlands; Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, 6525 Nijmegen, the Netherlands. Electronic address: dirk.lefeber@radboudumc.nl.

    Papers in Europe PMC
  7. 07
    Matthijs G6 papers · 2021

    Center for Human Genetics, University of Leuven, Leuven, Belgium.

    Papers in Europe PMC
  8. 08
    Edmondson AC5 papers · 2025

    Division of Human Genetics Department of Pediatrics Children's Hospital of Philadelphia Philadelphia PA.

    Papers in Europe PMC
  9. 09
    Eklund EA5 papers · 2024

    Department of Cell and Molecular Biology, Lund University, Lund, Sweden.

    Papers in Europe PMC
  10. 10
    Lam C5 papers · 2025

    National Human Genome Research Institute, NIH, Bethesda, Maryland.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"ALG8-CDG" OR "CDG syndrome type Ih" OR "CDG-Ih" OR "CDG1H" OR "Carbohydrate deficient glycoprotein syndrome type Ih" OR "Congenital disorder of glycosylation type 1h" OR "Congenital disorder of the glycosylation type 1h" OR "Congenital disorder of glycosylation type Ih" OR "Congenital disorder of the glycosylation type Ih" OR "Glucosyltransferase 2 deficiency" OR "ALG8-congenital disorder of glycosylation" OR "ALG8-congenital disorder of the glycosylation"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Congenital disorder of glycosylation type 1H

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"ALG8-CDG" OR "CDG syndrome type Ih" OR "CDG-Ih" OR "CDG1H" OR "Carbohydrate deficient glycoprotein syndrome type Ih" OR "Congenital disorder of glycosylation type 1h" OR "Congenital disorder of the glycosylation type 1h" OR "Congenital disorder of glycosylation type Ih" OR "Congenital disorder of the glycosylation type Ih" OR "Glucosyltransferase 2 deficiency" OR "ALG8-congenital disorder of glycosylation" OR "ALG8-congenital disorder of the glycosylation" OR "ALG8"

Recall-expansion terms: ALG8

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T02:17:45.018Z